bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but you need to cut through the technical jargon to understand what is happening under the hood. Here is the breakdown in plain English.

1. What does this company do?

BioAffinity is a medical technology company focused on early cancer detection. Their flagship product is a test called CyPath® Lung.

Instead of just looking for a tumor on a scan, their test uses flow cytometry to analyze cells in a patient’s sputum (phlegm). They use a special compound that binds to cancer cells, making them "light up" under a microscope. This helps laboratory technicians identify them. The test is a non-invasive, laboratory-developed test designed to help doctors diagnose lung cancer in high-risk patients. Their goal is to help clinicians catch lung cancer when it is still in the early, treatable stages.

2. How do they make money and are they growing?

The company is in the early stages of selling its product. They generate revenue by selling CyPath® Lung tests to physicians and clinics. However, the company is not yet profitable. For the fiscal year ending December 31, 2023, the company reported a loss of approximately $7.1 million. They spend heavily on research, development, and building their business. They rely on raising capital to fund operations until they sell enough tests to break even.

3. What’s the latest update?

The company is focused on getting more doctors to use CyPath® Lung. Because they are still growing, they must frequently raise money to fund their daily operations.

Why does this matter? It means the company is constantly seeking new funding. Every time they issue new shares or warrants, it causes "dilution." Think of it like a pizza: if the company keeps cutting more slices for new investors, your original slice of the company pie gets smaller. Investors should watch the company's "cash runway"—the amount of time they can operate before needing more money—as disclosed in their quarterly filings.

4. What are the main risks?

Investing in biotech is high-risk. Keep these factors in mind:

• Adoption Risk: They must convince doctors that CyPath® is better than, or a useful addition to, standard tools like low-dose CT scans.
• Insurance Coverage: The company’s success depends on getting insurance companies to pay for the test. If insurers do not cover it, patients may not pay out-of-pocket, which would limit sales.
• Cash Burn & Dilution: Because they are not profitable, they survive by selling more shares. This can lower the value of your shares over time.
• Regulatory Environment: The company operates under strict oversight. While they have internal policies regarding leadership liability, these do not override federal securities laws or SEC regulations.

5. Who’s running the company?

CEO Maria Zannes leads the company, bringing a background in law and public policy. The leadership team includes CFO J. Michael Edwards and a board of directors featuring Steven Girgenti, John Oppenheimer, Peter S. Knight, Roberto Rios, and Jamie Platt. They are responsible for navigating regulations and growing the business.

6. Where will it trade and under what symbol?

They are listed on the Nasdaq Capital Market under the ticker symbol "BIAF".

Disclaimer: I am an AI, not a financial advisor. Early-stage biotech stocks are volatile and carry a high risk of loss. Before you invest, take a moment to look at the company’s latest "10-K" or "10-Q" filings on the SEC’s EDGAR website. These documents contain the most accurate, up-to-date information regarding their financial health and specific risks.